
Background Thyroid hormone dysfunctions have long been related to mood disorders, but the causal relationship between parents’ thyroid dysfunctions and mood disorders of parents and offspring remains controversial. Methods To find this question, we administrated mice models of hyperthyroidism using L-thyroxin and hypothyroidism using lithium carbonate as well as using the three-chamber paradigm test, the elevated-plus maze (EPM) test, forced swimming test (FST), and tail suspension test (TST) for assessment of social, anxiety, and depression behaviors. Results The results of this research exhibited that treatment with L-thyroxin and lithium carbonate in parents had no significant effect on social motivation and novelty of parents and offspring in the three-chamber paradigm test (P > 0.05). Furthermore, induction of hyperthyroidism and hypothyroidism in parents caused anxiogenic-like behavior in parents and offspring via reduction of %OAT (P < 0.001) and %OAE (P < 0.01) but not locomotor activity (P > 0.05). Also, administration of L-thyroxin and lithium carbonate in parents induced depressant-like response in parents and offspring due to the enhancement of immobility time in the FST (P < 0.05) and TST (P < 0.05). Conclusions In conclusion, these findings suggested that induction of hyperthyroidism and hypothyroidism in parents induced anxiogenic- and depressant-like behaviors in parents and offspring.
Background Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disorder of the central nervous system characterized by neuroinflammation, oxidative stress, and progressive neuronal damage. This study investigated the neuroprotective effects of bromelain and vitamin D, administered individually or in combination, using pre- and post-treatment protocols in a rat model of ethidium bromide-induced demyelination. Materials and methods Focal demyelination was induced in adult male Wistar rats by stereotaxic injection of ethidium bromide. Animals were randomly assigned to control, demyelinated, bromelain-treated, vitamin D-treated, and combined treatment groups under pre- and post-treatment protocols. Brain tissue homogenates were analyzed for TNF-α, IL-27, IL-33, malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). Histopathological alterations and myelin basic protein (MBP) expression were also evaluated. Results Ethidium bromide-induced demyelination significantly increased TNF-α, IL-27, IL-33, and MDA levels while reducing SOD, CAT, and GPx activities compared with the control group (P < 0.0001). Combined bromelain and vitamin D treatment, particularly in the post-treatment protocol, significantly reduced TNF-α, IL-27, and MDA levels and increased SOD, CAT, and GPx activities (P < 0.05). However, IL-33 levels were not significantly affected. Combined therapy also attenuated demyelination, improved histopathological architecture, and enhanced MBP expression. Conclusion Combined bromelain and vitamin D treatment, particularly after lesion induction, effectively attenuated neuroinflammation and oxidative stress while preserving myelin integrity in ethidium bromide-induced demyelination. These findings suggest that this combination may represent a promising adjunctive therapeutic strategy for limiting demyelination-associated neural damage.
Introduction Sleep disruptions linked to adverse outcomes ranging from cognitive decline (e.g., in memory, learning, and sensory integration) to emotional dysregulation (e.g., stress and pathological anxiety). Although pre-sleep cognitive engagement may alleviate some of these effects, effective pharmacological interventions are needed. Ginkgo biloba, a dietary supplement, exerts broad pharmacological actions that support neural function. Here, we investigate hypothesis that Ginkgo biloba counteracts sleep deprivation’s detrimental effects by promoting BDNF-dependent neuroplasticity, thereby restoring cognitive and emotional homeostasis. Methods Twenty-eight male Wistar rats were randomly assigned to four groups: sleep disruption (SD) followed by Ginkgo biloba extract (250 mg/kg i.p.), sleep-disrupted group only, extract only, and control. The Ginkgo biloba collected from botanical garden of Tehran and the extract was prepared via percolation of plant material with ethanol, followed by evaporation and reconstitution. Animals were subjected to multiple-platform-induced sleep disruption (MPSD) for 2 h/day for 3 consecutive days. Behavioral assessments included the open-field test for stress/anxiety and the Barnes maze for spatial learning and memory over three days. Hippocampal BDNF levels were quantified using ELISA. Results Intraperitoneal Ginkgo biloba extract improved learning in sleep-disrupted rats, reducing probe-day latency from 71 ± 11 s (deprived) to 38 ± 8 s (p < 0.001); Ginkgo biloba alone yielded 15 ± 8 s. The open-field test revealed a significant increase in both locomotor speed and total distance traveled in the sleep-disrupted rats compared with the other experimental groups (P < 0.001). Sleep disruption reduced hippocampal BDNF from 544.55 ± 23–381.19 ± 17 pm/ml (p < 0.0001). Ginkgo biloba treatment significantly prevented this reduction (557 ± 27 pm/ml; p < 0.001) and, when administered alone, increased BDNF by 20% compared to controls (653 ± 25 pm/ml). Conclusion Sleep disruption impaired memory and learning but did not significantly affect anxiety. Treatment with Ginkgo biloba extract (250 mg/kg) improved memory and reduced anxiety. Hippocampal BDNF changes suggest restorative effects may be mediated by increasing BDNF levels reduced by deprivation. As an Iranian Ginkgo biloba extract was used, further research is needed to identify optimal extraction methods and phytochemical compositions for enhancing BDNF levels, thereby optimizing therapeutic potential of Ginkgo biloba -derived compounds for sleep and cognitive applications.